Industrialising organoids for the next generation of drug discovery
New synthetic 3D gel technology for cell culture promises to unlock the potential of ‘mini-organs’ for industrial drug discovery.
List view / Grid view
Articles
Clinical optimism for antagonists targeting certain ion channels
Adenosine triphosphate (ATP)-gated ion channels serve important neurophysiological functions and have been an attractive class of drug target for a decade...
Translational proteomics: from the bench to the bedside
Understanding how a cell responds to different stimuli producing diverse protein profiles can provide information about cell signalling pathways, generating more specific treatments...
Tackling the spread of pathogens in transport hubs
Ilpo Kulmala, Principal Scientist at VTT Ltd, explains the role that transportation plays in the spread of infectious diseases...
Exploring the need for mutation-specific treatments in cystic fibrosis
Despite that over 1,900 mutations of the cystic fibrosis transmembrane conductance regulator cause cystic fibrosis, only two treatment options exist.
Screening In-Depth Focus 2016
In this Screening In-Depth Focus, scientists from the Assay Development and Screening Platform of Helmholtz Zentrum München provide an overview of different high-throughput screening (HTS)-applicable assay types that can be applied to drug discovery campaigns. Plus an interview with Lee Babiss, CEO of drug discovery firm X-Rx, on the benefits…
Personalised Medicines In-Depth Focus 2016
In this Personalised Medicines In-Depth Focus, Dr Adrian Harel talks about the importance of developing a diagnostic test and better treatments for traumatic brain injury. Plus, Caroline Richards, Editor of Drug Target Review explores the need for mutation specific treatments in cystic fibrosis...
Next-Generation Sequencing In-Depth Focus 2016
NGS technologies have been employed in a wide range of areas in drug discovery, including drug target identification, biomarker discovery and biopharmaceutics development. Pushpanathan Muthuirulan of the National Institutes of Health gives us an overview of this in his article in our NGS In-Depth Focus. Meanwhile, the possibilities that RNA-Seq…
Drug Target Review – Issue #4 2016
11 December 2016 | By Drug Target Review
Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs...
Valid biomarker signatures from liquid biopsies – how to standardise NGS
The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…
How artificial intelligence is the future of pharma
5 December 2016 | By Professor Jackie Hunter, BenevolentBio
Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...
Versatile applications of next-generation sequencing in pharmaceutics
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes
The covalent modification of proteins by the attachment of ubiquitin (ubiquitination) is best known for its function to label proteins for proteasomal degradation. However, ubiquitination also plays non-proteasomal roles during signal transduction, DNA repair and protein sorting...
How to be a research scientist: A conversation with Novo Nordisk’s Rahul Kapur
23 November 2016 | By Rahul Kapur, Head of Medical Affairs, Novo Nordisk UK and Ireland
We caught up with Novo Nordisk’s Rahul Kapur, to find out what it’s like to be at the forefront of diabetes research and what it takes to get there...
D is for Diabetes
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
D is for Diabetes - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research into Diabetes...